• Explore /
  • Poster
  • / Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.

Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.

Abstract Poster

Authors

null

Astrid Blom Fily

CHU Ambroise Paré, Boulogne-Billancourt, France

Astrid Blom Fily , Laurent Mortier , Isabelle Kachaner , Nicolas Meyer , Mahtab Samimi , Laura Luciani , Capucine Cahuzac , Caroline Robert , Gaëlle Quéreux , Eve Maubec , Cathy Maillard , Hakima Miotti , François Aubin , Cédric Lenormand , Marie-Noelle Solbes , Pascal Joly , Benoît van Hille , Celeste Lebbe , Caroline Dutriaux , Philippe Saiag

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9537)

DOI

10.1200/JCO.2023.41.16_suppl.9537

Abstract #

9537

Poster Bd #

300

Abstract Disclosures

Similar Posters

First Author: Syvart Dennen

First Author: Kelly N. Fitzgerald

First Author: Abhijeet Bhanegaonkar

First Author: Sandra P. D'Angelo